Blood Test Increases Accuracy in Prenatal Testing
|
By LabMedica International staff writers Posted on 22 Nov 2015 |

Image: The Qubit Fluorometer accurately detects and quantifies very low concentrations of DNA, RNA, and protein (Photo courtesy of Great Lakes Genomics Center).
A simple, accurate and low risk blood test can detect fetal blood group, sex, and genetic conditions in unborn babies and the DNA test is inexpensive and is noninvasive, as opposed to the traditional amniocentesis test that involves a needle and carries a minor risk of miscarriage.
Laboratory methods have been evaluated for noninvasive genotyping of fetal RHD (Rh blood group, D antigen) that can prevent the unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The test developed can be carried out on mothers at risk of X-linked genetic recessive diseases including hemophilia and Duchenne muscular dystrophy and mothers at risk of hemolytic disease of the new-born.
Scientists at the University of Plymouth (UK) recruited RHD-negative pregnant women (28 to 30 weeks' gestation), all of whom met inclusion criteria, from November 2013 to September 2014. Twenty-two maternal peripheral blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) tubes and centrifuged at 1,600×g for 10 minutes at room temperature (samples 1–22). The plasma was carefully removed and transferred to a 15-mL tube. The plasma was then re-centrifuged at 16,000×g for 10 minutes.
Twenty-four maternal blood samples collected in Streck Cell-Free DNA blood collection tubes (Streck BCTs; La Vista, NE, USA) were centrifuged at 1,600×g for 15 minutes at room temperature (samples 23–46). Plasma was carefully removed, transferred to a 50-mL tube, and re-centrifuged at 2,500×g for 10 minutes. DNA was extracted from two 1-mL aliquots of plasma and quantified samples on the Qubit 2.0 Fluorometer (Thermo Fisher; Waltham, MA, USA). Using Y-specific and RHD-specific targets, the team investigated variation in the cell-free fetal DNA (cffDNA) fraction and determined the sensitivity achieved for optimal and suboptimal samples with a novel Droplet Digital polymerase chain reaction (ddPCR, Bio-Rad Laboratories; Hercules CA, USA) platform compared with real-time quantitative PCR (qPCR).
The cffDNA fraction was significantly larger for samples collected in Streck BCTs compared with samples collected in EDTA tubes. In samples expressing optimal cffDNA fractions greater than 4%, both qPCR and ddPCR showed 100% sensitivity for the testis-specific protein, Y-linked 1(TSPY1) and RHD exon 7 (RHD7) assays. Although ddPCR also had 100% sensitivity for RHD exon 5 (RHD5), qPCR had reduced sensitivity (83%) for this target. For samples expressing suboptimal cffDNA fractions, less than 2%, ddPCR achieved 100% sensitivity for all assays, whereas qPCR achieved 100% sensitivity only for the TSPY1 multicopy target assay.
Neil D. Avent, PhD, a professor and lead author of the study, said, “Although fetal blood grouping and sexing using maternal blood has been done for over a decade, this study proves a much more accurate and sensitive method of detecting fetal DNA. This offers great opportunities to detect other conditions using this technique, but is much cheaper than current noninvasive methods. The end is now in sight for the invasive techniques of amniocentesis and chorionic villus sampling.” The study was published in the November 2015 issue of the journal Clinical Chemistry.
Related Links:
University of Plymouth
Streck
Thermo Fisher
Laboratory methods have been evaluated for noninvasive genotyping of fetal RHD (Rh blood group, D antigen) that can prevent the unnecessary administration of prophylactic anti-D to women carrying RHD-negative fetuses. The test developed can be carried out on mothers at risk of X-linked genetic recessive diseases including hemophilia and Duchenne muscular dystrophy and mothers at risk of hemolytic disease of the new-born.
Scientists at the University of Plymouth (UK) recruited RHD-negative pregnant women (28 to 30 weeks' gestation), all of whom met inclusion criteria, from November 2013 to September 2014. Twenty-two maternal peripheral blood samples were collected in Ethylenediaminetetraacetic acid (EDTA) tubes and centrifuged at 1,600×g for 10 minutes at room temperature (samples 1–22). The plasma was carefully removed and transferred to a 15-mL tube. The plasma was then re-centrifuged at 16,000×g for 10 minutes.
Twenty-four maternal blood samples collected in Streck Cell-Free DNA blood collection tubes (Streck BCTs; La Vista, NE, USA) were centrifuged at 1,600×g for 15 minutes at room temperature (samples 23–46). Plasma was carefully removed, transferred to a 50-mL tube, and re-centrifuged at 2,500×g for 10 minutes. DNA was extracted from two 1-mL aliquots of plasma and quantified samples on the Qubit 2.0 Fluorometer (Thermo Fisher; Waltham, MA, USA). Using Y-specific and RHD-specific targets, the team investigated variation in the cell-free fetal DNA (cffDNA) fraction and determined the sensitivity achieved for optimal and suboptimal samples with a novel Droplet Digital polymerase chain reaction (ddPCR, Bio-Rad Laboratories; Hercules CA, USA) platform compared with real-time quantitative PCR (qPCR).
The cffDNA fraction was significantly larger for samples collected in Streck BCTs compared with samples collected in EDTA tubes. In samples expressing optimal cffDNA fractions greater than 4%, both qPCR and ddPCR showed 100% sensitivity for the testis-specific protein, Y-linked 1(TSPY1) and RHD exon 7 (RHD7) assays. Although ddPCR also had 100% sensitivity for RHD exon 5 (RHD5), qPCR had reduced sensitivity (83%) for this target. For samples expressing suboptimal cffDNA fractions, less than 2%, ddPCR achieved 100% sensitivity for all assays, whereas qPCR achieved 100% sensitivity only for the TSPY1 multicopy target assay.
Neil D. Avent, PhD, a professor and lead author of the study, said, “Although fetal blood grouping and sexing using maternal blood has been done for over a decade, this study proves a much more accurate and sensitive method of detecting fetal DNA. This offers great opportunities to detect other conditions using this technique, but is much cheaper than current noninvasive methods. The end is now in sight for the invasive techniques of amniocentesis and chorionic villus sampling.” The study was published in the November 2015 issue of the journal Clinical Chemistry.
Related Links:
University of Plymouth
Streck
Thermo Fisher
Latest Molecular Diagnostics News
- AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
- AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
- AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
- Liquid Biopsy Expands Insights Into Treatment Response and Tumor Alterations
- Blood Test Identifies Candidates for Targeted Radiotherapy in Advanced Prostate Cancer
- Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
- Liquid Biopsy Captures Gene Activity Patterns in Small-Cell Lung Cancer
- Genomic Sequencing Identifies Actionable Findings to Guide Rare Disease Management
- Combined Blood Tests Help Clarify Colorectal Cancer Recurrence Risk
- Blood RNA Test May Detect Precursors to Ovarian Cancer
- Microsatellite Instability Test Gains FDA Approval for Immunotherapy Selection
- Blood-Detected Chromosomal Changes May Refine Colorectal Cancer Risk Assessment
- AI Tool Automates Variant Curation and Interpretation for Cancer Whole-Genome Sequencing
- Portable Test Detects Zika and Hepatitis C RNA from Whole Blood
- DNA Methylation May Predict Treatment Response in Myelodysplastic Syndromes
- Blood-Based Test May Predict Response Across Rheumatoid Arthritis Drug Classes
Channels
Clinical Chemistry
view channel
AI Predicts Kidney Stone Composition From Routine Urine Tests
Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. Identifying stone composition is important for guiding treatment... Read more
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







